GLP-1 receptor agonists like semaglutide and liraglutide present unexpected complications for cancer patients receiving radiation therapy. These increasingly popular medications cause significant weight loss and delayed gastric emptying that can disrupt the precise anatomical positioning required for effective radiation treatment. Radiation therapy depends on weight stability and consistent organ positioning to accurately target tumors while sparing healthy tissue. The clinical intersection highlights a growing medical complexity as GLP-1 drugs become mainstream treatments for diabetes, obesity, and metabolic disease. An estimated 12 million Americans now use these medications, creating a substantial population potentially affected by treatment interactions. The finding underscores how breakthrough therapies can create unintended downstream effects across medical specialties. Oncologists may need to adjust radiation protocols, implement adaptive techniques, or coordinate medication timing with endocrinologists. This represents an emerging challenge in precision medicine where successful treatments in one domain create complications in another. The authors' call for consensus recommendations reflects the urgent need for interdisciplinary protocols as drug adoption outpaces clinical guidelines for complex patient populations.